Loading...

VTGN VISTAGEN THERAPEUTICS INC Product Launches 8-K Filing

VSTG

VTGN

VISTAGEN THERAPEUTICS INC

(VTGN)

2025 8-K

New Corporate Presentation

Study Results Update

Management Change

Financial Results Update

Clinical Trial Update

Director Appointment

Management Changes

Financial Statements

Equity Offerings

Product Expansion

Earnings Report

Earnings Report

Earnings Report

Earnings Report

Earnings Report

Earnings Report

Earnings Report

Filing Letter with Quantita...

Filing with Quantitative Data

Filing with Quantitative Data

Quantitative Data

Filing with Quantitative Data

Filing with Quantitative Data

Quantitative Data

Quantitative Data

Quantitative Data

Filing with Quantitative Data

Underwriting Agreement

Quantitative Data

Update on Progress and Fina...

Filing with Quantitative Data

Filing with Quantitative Data

Other Special Situation

Filing Letter with Financia...

Other Special Situation

Filing with Quantitative Data

Financial Update

Filing with Quantitative Data

Quantitative Data

Quantitative Data

Filing with Quantitative Data

Filing with Quantitative Data

Quantitative Data

Other Special Situation

Filing Letter with Quantita...

Other Special Situation

Filing with Quantitative Data

Filing Letter with Quantita...

Update on Clinical Developm...

External Links:

On November 3, 2025, Vistagen Therapeutics, Inc. announced the completion of the public speaking challenge phase in their PALISADE-3 clinical trial for fasedienol, aimed at treating social anxiety disorder.

AI Assistant

VISTAGEN THERAPEUTICS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.